Indaptus Therapeutics, Inc. 8-K

What Happened
Indaptus Therapeutics, Inc. (INDP) announced on June 17, 2026 that it entered into a Stock Purchase Agreement to privately sell 20,000,000 shares of common stock at $0.60 per share. The Private Placement generated approximately $12,000,000 in gross proceeds and closed the same day.

Key Details

• 20,000,000 shares of common stock sold at $0.60 per share; gross proceeds ≈ $12,000,000.
• The shares represented less than 20% of the Company’s issued and outstanding common stock prior to the agreement.
• Purchasers are non‑U.S. accredited investors and the offering was made in reliance on Regulation S (unregistered sale).
• Company must file an SEC registration statement to register resale of the shares within 90 days of closing and use best efforts to have it declared effective within 75 days after filing (company will pay related registration fees); no placement commissions were paid.

Why It Matters
This transaction provides Indaptus with immediate capital (~$12M) without paying placement fees, which can fund operations or corporate needs. Because the shares were sold privately to non‑U.S. investors and are subject to registration rights, those shares may become freely tradable after the Company’s required SEC registration becomes effective. The issuance also increases the company’s outstanding share count (dilution), though the filing notes the sale was under 20% of prior outstanding shares.